Floatz logo

MIDAZOLAM

Depression, Bipolar

New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Depression, Bipolar cohort.

Asset / SponsorPhaseRating
Olanzapine
China Medical University, China
Phase 4BBB
ZIPRASIDONE
Queen's University
Phase 4BBB
Valproic Acid
Ewha Womans University Mokdong Hospital
Phase 4BB
Cariprazine
Aalborg University Hospital
Phase 4BB
Starch
China Medical University, China
Phase 4BB

View all 23 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →